Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term study of OPC-262 in patients with type 2 diabetes mellitus
jRCT2080220920Phase 3
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by Otsuka Pharmaceutical Co., Ltd.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080220920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220920.